A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial

BACKGROUND: Preclinical studies in breast cancer models showed that BRCA1 or BRCA2 deficient cell lines, when compared to BRCA proficient cell lines, are extremely sensitive to PARP1 inhibition. When combining the PARP1 inhibitor olaparib with cisplatin in a BRCA1-mutated breast cancer mouse model,...

Descripción completa

Detalles Bibliográficos
Autores principales: Schouten, Philip C., Dackus, Gwen M. H. E., Marchetti, Serena, van Tinteren, Harm, Sonke, Gabe S., Schellens, Jan H. M., Linn, Sabine C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915081/
https://www.ncbi.nlm.nih.gov/pubmed/27323902
http://dx.doi.org/10.1186/s13063-016-1423-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915081/
https://www.ncbi.nlm.nih.gov/pubmed/27323902
http://dx.doi.org/10.1186/s13063-016-1423-0

Ejemplares similares